Priyabrata Mukherjee to Female
This is a "connection" page, showing publications Priyabrata Mukherjee has written about Female.
Connection Strength
0.657
-
MicroRNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Rep. 2020 10 05; 21(10):e48483.
Score: 0.057
-
Gold Nanoparticles Disrupt Tumor Microenvironment - Endothelial Cell Cross Talk To Inhibit Angiogenic Phenotypes in Vitro. Bioconjug Chem. 2019 06 19; 30(6):1724-1733.
Score: 0.052
-
Cystathionine ß-synthase regulates mitochondrial morphogenesis in ovarian cancer. FASEB J. 2018 08; 32(8):4145-4157.
Score: 0.048
-
MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
Score: 0.045
-
Role of cystathionine beta synthase in lipid metabolism in ovarian cancer. Oncotarget. 2015 Nov 10; 6(35):37367-84.
Score: 0.041
-
Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget. 2014 Aug 15; 5(15):6453-65.
Score: 0.037
-
Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. Bioconjug Chem. 2014 Jun 18; 25(6):1078-90.
Score: 0.037
-
Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167.
Score: 0.035
-
Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. J Biol Chem. 2013 Jun 14; 288(24):17610-8.
Score: 0.034
-
Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6700-5.
Score: 0.034
-
Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One. 2012; 7(3):e33650.
Score: 0.032
-
MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009 Dec 01; 69(23):9090-5.
Score: 0.027
-
Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7659-66.
Score: 0.025
-
Vascular Endothelial Growth Factor as an Immediate-Early Activator of Ultraviolet-Induced Skin Injury. Mayo Clin Proc. 2022 01; 97(1):154-164.
Score: 0.015
-
Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer. ACS Appl Mater Interfaces. 2021 Oct 27; 13(42):49614-49630.
Score: 0.015
-
Improved pentamethine cyanine nanosensors for optoacoustic imaging of pancreatic cancer. Sci Rep. 2021 02 23; 11(1):4366.
Score: 0.015
-
KRCC1: A potential therapeutic target in ovarian cancer. FASEB J. 2020 02; 34(2):2287-2300.
Score: 0.013
-
Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther. 2018 10; 17(10):2136-2143.
Score: 0.012
-
LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res. 2018 04 15; 78(8):1923-1934.
Score: 0.012
-
Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 01; 17(1):39-49.
Score: 0.012
-
BMI1, a new target of CK2a. Mol Cancer. 2017 03 07; 16(1):56.
Score: 0.011
-
Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget. 2016 Nov 08; 7(45):72845-72859.
Score: 0.011
-
MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochim Biophys Acta. 2016 08; 1859(8):983-93.
Score: 0.011
-
Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
Score: 0.010
-
Hepatoma derived growth factor (HDGF) dynamics in ovarian cancer cells. Apoptosis. 2016 Mar; 21(3):329-39.
Score: 0.010
-
Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918.
Score: 0.007